All Opportunities
HHS-FDA
FOR-FD-26-004
discretionary
Forecasted

Novel approaches to support therapeutic development in ultra-rare cancers

Food and Drug AdministrationPosted August 4, 2025

Official Federal Notice

View the complete notice on Grants.gov

View on Grants.gov

Summary

The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Specific areas of interest include, but are not limited to, the following examples: • Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers. • Investigations to explore opportunities to develop...
Read full notice on Grants.gov

Eligible Applicants

  • Independent school districts
  • State governments
  • Nonprofits (non-501(c)(3))
  • Federally recognized tribal governments
  • County governments
  • Public institutions of higher education
  • For-profit organizations
  • Other tribal organizations
  • Small businesses
  • Nonprofits (501(c)(3))
  • Public And Indian Housing Authorities
  • Special district governments
  • Private institutions of higher education
  • City or township governments

Assistance Listings

93.103
Food and Drug Administration Research

Funding Instrument

Cooperative Agreement

CFDA / Assistance Listing Numbers

93.103

Topics

Program Contact

Information on this page is sourced from official federal notices on Grants.gov. Always verify eligibility, deadlines, and requirements using the official notice. Funding Radar is not affiliated with the U.S. government.

Key Details

Expected Awards

2

Posted

August 4, 2025

Cost Sharing

Not Required

Agency

HHS-FDA

View Official Notice

Data from Grants.gov

Last fetched: 3/23/2026